NIPT (noninvasive prenatal testing) works by analyzing tiny fragments of DNA floating in a pregnant person’s blood. Some of these fragments come from the placenta and carry the baby’s genetic information, allowing labs to check for chromosomal conditions like Down syndrome without any needle or probe touching the uterus. The test is a simple blood draw, typically done from 10 weeks of pregnancy onward, and it catches over 99% of Down syndrome cases.
How DNA Gets Into Your Blood
Throughout pregnancy, cells in the placenta naturally break down and die in a process called apoptosis. As these cells break apart, they release short fragments of DNA into the mother’s bloodstream. These fragments, called cell-free DNA, mix with the mother’s own circulating DNA fragments. Because the placenta is genetically almost identical to the fetus, analyzing these fragments gives a window into the baby’s chromosomes.
By about 10 weeks of pregnancy, roughly 10% of the free-floating DNA in your blood comes from the placenta. This percentage, known as the fetal fraction, is the key to making the test work. Labs generally need a fetal fraction between 2% and 4% at minimum to produce a reliable result. Before 10 weeks, the fetal fraction is often too low, which is why most providers don’t order the test earlier.
What Happens in the Lab
After your blood is drawn, the lab extracts all the cell-free DNA from the plasma (the liquid part of your blood). This pool contains both your DNA and the baby’s. Sophisticated sequencing technology reads millions of these tiny DNA fragments and maps them back to the chromosomes they came from.
The basic idea is a counting game. A baby with Down syndrome has three copies of chromosome 21 instead of two, so the placenta sheds slightly more chromosome 21 material into the mother’s blood than expected. The lab’s software detects this statistical excess. If the amount of DNA from a particular chromosome is higher than the normal range, the result comes back as high-risk for that condition. The same logic applies to other chromosomal conditions: too much material from chromosome 18 signals Edwards syndrome, and too much from chromosome 13 signals Patau syndrome.
What NIPT Screens For
The core panel covers the three most common trisomies: trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Most labs also offer optional screening for sex chromosome differences, such as Turner syndrome or Klinefelter syndrome, and can report the baby’s sex.
Some companies market expanded panels that screen for smaller missing pieces of chromosomes, called microdeletions. However, the American College of Obstetricians and Gynecologists does not recommend routine screening for microdeletions. The evidence behind these expanded panels is limited in the general population, and the false positive rate is higher. If you’re interested in that level of detail, diagnostic testing like amniocentesis is more reliable.
How Accurate It Is
For Down syndrome specifically, NIPT catches about 99.3% of cases, with a specificity of 99.9%. That means it misses very few affected pregnancies and rarely flags unaffected ones. For Edwards and Patau syndromes, detection rates are slightly lower but still strong, around 97% for both. These numbers are substantially better than older screening methods like the first-trimester blood test combined with ultrasound.
But accuracy has a nuance that trips people up. A test can be highly sensitive and specific and still produce a positive result that turns out to be wrong. This is because the positive predictive value (how likely a positive result is truly positive) depends on how common the condition is in your age group. In one large study of women over 35, the positive predictive value for Down syndrome was about 91%, meaning roughly 9 out of 100 high-risk results were false alarms. For rarer conditions like trisomy 13, the positive predictive value dropped to about 28%, even in this higher-risk group. In younger women, where these conditions are less common, the false positive rate is proportionally higher.
Why It’s a Screening Test, Not a Diagnosis
NIPT reads DNA from the placenta, not from the baby directly. In most pregnancies, the placenta’s chromosomes match the baby’s perfectly. But occasionally the placenta develops chromosomal differences that the baby doesn’t share, a phenomenon called confined placental mosaicism. This is the most common biological reason for a false positive. A vanishing twin (a twin pregnancy where one embryo stopped developing early) can also leave behind DNA that skews results.
This is why a positive NIPT result is never treated as a final answer. Current guidelines recommend that any high-risk result be followed by genetic counseling and a diagnostic procedure, either chorionic villus sampling (CVS) or amniocentesis. These tests analyze cells from the baby directly and provide a definitive yes or no. Amniocentesis remains the gold standard for confirming chromosomal conditions prenatally.
When Results Can’t Be Reported
Sometimes the lab can’t produce a result at all, typically because the fetal fraction was too low. This happens more often in early pregnancy, but maternal weight is the most significant ongoing factor. Among women with a normal BMI, about 4.5% of samples have a fetal fraction below the usable threshold. That rate jumps to nearly 20% in women with a BMI over 30 and reaches 35.5% in women with a BMI of 40 or higher.
When a result is non-reportable, labs will often try reprocessing the same sample or request a second blood draw. Reprocessing succeeds about 79% of the time for normal-weight women, but only 56% of the time for women with obesity. The reason is straightforward: a larger body produces more of its own cell-free DNA, which dilutes the baby’s share. A non-reportable result doesn’t mean something is wrong with the baby, but it does carry a slightly increased statistical risk for aneuploidy, so providers typically recommend genetic counseling and may suggest diagnostic testing.
Timing and What to Expect
Most providers offer NIPT starting at 10 weeks of gestation. Fetal DNA is detectable in maternal blood as early as five weeks, but the concentration is too low for reliable analysis until around week 10. The test itself is just a standard blood draw from your arm, with no preparation needed.
Results typically come back within one to two weeks. You’ll receive either a low-risk or high-risk result for each condition tested. NIPT works in twin pregnancies too, and current guidelines recommend it as a first-line screening option for trisomies 21, 18, and 13 in twins. However, sex chromosome screening in twin pregnancies and screening in higher-order multiples (triplets or more) are not recommended due to lack of data.
Who Should Be Offered NIPT
NIPT was originally reserved for women considered high-risk due to age or family history. That’s changed. As of late 2025, ACOG recommends that cell-free DNA screening for trisomies 21, 18, and 13 be routinely available to all pregnant patients, regardless of age or risk level. The evidence shows it outperforms traditional screening in every patient population. That said, the decision to screen is always yours. Prenatal genetic screening is optional, and every patient has the right to pursue or decline it after appropriate counseling.